The EUROclass trial: defining subgroups in common variable immunodeficiencyClaudia Wehr, Klaus Warnatz, Drahomíra Detková et al.|Blood|2007Cited by 860
High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patientsSammy Huygens, Bart Rijnders, Arvind Gharbharan et al.|Journal of Antimicrobial Chemotherapy|2023Cited by 23
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization studyPauline M. Ellerbroek, Leman Yel, Leif G. Hanitsch et al.|Immunotherapy|2024Cited by 5
Novel <i>STAT3</i> Y360C Gain-of-function Variant Underlies Immune Dysregulation and Aberrancy in Mitochondrial DynamicsKornvalee Meesilpavikkai, P. Martin van Hagen|Immune Network|2025Cited by 2